This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Two China Pharma Plays

With $15 million in cash, about $12 million in annual operating cash flow and the potential for $25 million from warrants conversions, Tianyin has the war chest to pursue accretive acquisitions that may give upside to guidance. Bullish commentary from a recent press release elaborates on the Company's view which emphasizes that

"commercializing and broadening our product line coupled with the expansion of our production facility and capacity should continue to yield significant increases in revenue in 2010 and beyond."

While short-term investors may still approach TPI with trepidation, astute long-term investors may be begin to notice the opportunity, especially given the company's overall strong fundamental story. The stock is trading at a forward P/E of 8 on our implied EPS guidance of 50 cents per share.

Biostar Pharmaceuticals (BSPM - Get Report) is another pharmaceutical company whose stock we own. In our interview with management, BSPM demonstrated that it has a coherent understanding of its markets and the steps necessary to accelerate growth.



Biostar manufactures and distributes 15 nonprescription, prescription and nutraceutical products.

Three aspects of Biostar's story are worth considering. First, its Hepatitis flagship drug is the only one offered over the counter in Chinese drug stores. Through our communication with Biostar CEO Ronghua Wang, we learned that two other companies have the licenses for such a drug, but failed to compete due to management's lack of market awareness.

He elaborated that one of the companies, instead of choosing to market capsules as Biostar had done, marketed cheaper and underperforming tablets which ultimately led to failure.

He also stressed that the Chinese government is not issuing anymore over-the-counter Hepatitis drug licenses and has chosen to limit advertising campaigns for prescription only Hepatitis manufacturers. This provides a significant barrier to entry. At an average cost of $2 day, this treatment is the most cost effective on the market.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BSPM $1.14 0.00%
TPI $0.60 0.00%
AAPL $128.46 0.00%
FB $78.97 0.00%
GOOG $558.40 0.00%

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs